Supraventricular tachycardia (SVT)

Supraventricular tachycardia, commonly abbreviated as SVT, is a category of abnormally rapid heart rhythms that originate above the ventricles in the atria or atrioventricular junction of a cat's heart. This arrhythmia is characterized by heart rates that exceed normal physiological limits and occur suddenly without appropriate physiological triggers such as exercise or stress. SVT encompasses several specific arrhythmia types including atrial tachycardia, atrioventricular nodal reentrant tachycardia, and accessory pathway-mediated tachycardias. While less common than some other cardiac arrhythmias in cats, SVT can cause significant clinical symptoms and may indicate underlying cardiac disease requiring comprehensive evaluation.

The development of SVT involves abnormal electrical activity in the upper chambers of the heart or the conduction pathways connecting the atria to the ventricles. Unlike normal heart rhythm where the sinoatrial node initiates each beat at an appropriate rate, SVT occurs when abnormal electrical circuits or ectopic foci generate rapid impulses that override normal pacemaker function. These rapid rhythms may be sustained, lasting minutes to hours, or may occur in brief paroxysms that start and stop suddenly. The heart rates achieved during SVT episodes often exceed 300 beats per minute in cats, far above the normal resting rate of 120 to 200 beats per minute.

The clinical significance of SVT in cats depends on the ventricular rate achieved, episode duration, frequency of recurrence, and underlying cardiac health. Brief episodes of SVT in cats with otherwise normal hearts may cause minimal symptoms and may resolve spontaneously. However, prolonged or frequently recurring SVT compromises cardiac function by reducing the time available for ventricular filling between beats, decreasing cardiac output. Cats with underlying heart disease are particularly vulnerable to hemodynamic compromise during SVT episodes. Sustained rapid rates can lead to tachycardia-induced cardiomyopathy, where the persistent fast heart rate itself causes progressive cardiac dysfunction.

Treatment for SVT in cats focuses on controlling ventricular rate during episodes, preventing recurrence, and addressing any underlying cardiac disease. Various medications can slow conduction through the atrioventricular node or suppress ectopic atrial activity. Acute episodes may require emergency intervention including vagal maneuvers or cardioversion. Long-term management involves daily oral medications selected based on individual patient response and tolerance. Working with a veterinarian experienced in cardiac disease or a veterinary cardiologist ensures accurate diagnosis, appropriate treatment selection, and optimal outcomes for cats with SVT.

The causes of supraventricular tachycardia in cats involve abnormalities in cardiac electrical conduction that allow rapid, repetitive activation of the atria or atrioventricular junction. The most common mechanism underlying SVT is reentry, where electrical impulses travel in circular pathways, continuously re-exciting cardiac tissue rather than following the normal single-pass conduction pattern. Reentrant circuits can form within the atrial tissue, within the atrioventricular node, or between the normal conduction system and accessory pathways that bypass the atrioventricular node. Enhanced automaticity, where ectopic foci in atrial tissue generate impulses faster than the sinoatrial node, represents another mechanism causing some forms of SVT.

Structural heart disease significantly predisposes cats to SVT development through several mechanisms. Hypertrophic cardiomyopathy, the most common feline heart disease, causes atrial enlargement and atrial myocardial changes that promote arrhythmia development. Dilated cardiomyopathy, restrictive cardiomyopathy, and other structural cardiac abnormalities similarly affect atrial architecture and electrical properties. Atrial enlargement from any cause, including congenital heart defects or acquired valve disease, stretches atrial tissue and disrupts normal electrical conduction patterns. Myocardial fibrosis, inflammation, or infiltration can create the heterogeneous tissue properties necessary for reentrant circuit formation.

Genetic factors contribute to SVT susceptibility both through their effects on cardiac structure and potentially through direct effects on cardiac electrophysiology. Breeds predisposed to cardiomyopathy, including Maine Coons, Ragdolls, and British Shorthairs, face elevated arrhythmia risk secondary to their cardiac disease predisposition. Genetic mutations affecting ion channels or conduction proteins could theoretically cause primary electrical abnormalities predisposing to SVT, though specific genetic causes have not been well characterized in cats. Familial clustering of arrhythmias in some cat populations suggests heritable factors beyond those related to structural heart disease.

Systemic conditions and external factors can trigger or exacerbate SVT in susceptible cats. Hyperthyroidism dramatically increases the risk of SVT and other tachyarrhythmias through its effects on cardiac metabolism and sensitivity to catecholamines. Electrolyte disturbances, particularly abnormalities in potassium, magnesium, or calcium, affect cardiac electrical stability. Anemia increases cardiac workload and may trigger arrhythmias. Fever, pain, and anxiety cause sympathetic nervous system activation that can initiate or sustain SVT. Certain medications and toxins, including some anesthetic agents and sympathomimetic drugs, may provoke SVT in predisposed individuals.

The mechanism by which SVT develops typically involves either reentry or enhanced automaticity overwhelming normal cardiac rhythm control. In reentrant SVT, an electrical impulse encounters tissue with different conduction properties, allowing the impulse to travel in a circular path and repeatedly activate the heart. This circular conduction continues until interrupted by medication, vagal maneuvers, or spontaneous termination. In automatic SVT, ectopic pacemaker cells in the atria fire at rates exceeding the sinoatrial node, taking over cardiac rhythm control. Both mechanisms result in rapid, regular atrial activation that may or may not conduct completely to the ventricles depending on atrioventricular node properties.

Early warning signs of supraventricular tachycardia in cats may be subtle, particularly when episodes are brief or infrequent. Some cats display transient changes in behavior or activity that coincide with arrhythmia episodes but resolve quickly, leaving owners uncertain about whether they witnessed anything significant. Mild restlessness, sudden cessation of activity, or brief periods of unusual stillness may occur during SVT episodes. Attentive owners might notice their cat's heart racing by feeling the chest or noting visible rapid chest wall movement during episodes. Between episodes, cats may appear completely normal, making symptom recognition challenging without prolonged observation.

Common symptoms of clinically significant SVT reflect compromised cardiac output during rapid heart rates. Exercise intolerance develops as the heart cannot effectively meet increased oxygen demands during activity. General weakness or lethargy may occur, particularly following or during prolonged arrhythmia episodes. Some cats show decreased appetite during symptomatic periods. Restlessness and apparent anxiety may reflect the cat's awareness of abnormal cardiac sensations. Panting or open-mouth breathing, unusual in cats, may occur during severe episodes as respiratory rate increases to compensate for reduced oxygen delivery.

Behavioral changes associated with SVT often manifest as alterations in activity patterns and social engagement. Affected cats may avoid physical exertion, declining to play or choosing not to jump onto previously favored elevated surfaces. Hiding behavior may increase, with cats seeking quiet, secure locations during symptomatic periods. Changes in sleep patterns, including increased sleeping or restlessness during sleep, may occur. Some cats vocalize more during episodes, potentially reflecting distress or confusion. Appetite fluctuations correlate with symptom severity, with reduced eating during active arrhythmia episodes.

Physical signs detectable during SVT episodes include dramatically elevated heart rate, often exceeding 300 beats per minute, with a regular rhythm in most cases. The peripheral pulse may be weak or difficult to palpate despite the rapid heart rate due to reduced ventricular filling and stroke volume. Mucous membranes may appear pale or slightly blue if cardiac output is significantly compromised. Respiratory rate and effort often increase during symptomatic episodes. Between episodes, physical examination may be completely normal, highlighting the importance of capturing arrhythmia on ECG during active symptoms.

Symptom progression in cats with untreated or poorly controlled SVT typically involves increasing episode frequency and severity over time. Initial brief, self-terminating episodes may progress to more prolonged arrhythmias requiring medical intervention. As episodes become more frequent, cumulative effects on cardiac function may develop, potentially leading to tachycardia-induced cardiomyopathy with progressive heart dysfunction. Cats with underlying structural heart disease may experience accelerated progression of heart failure symptoms. The transition from compensated to decompensated cardiac function can be gradual or sudden.

Emergency symptoms requiring immediate veterinary attention include collapse or syncope during SVT episodes, severe respiratory distress with open-mouth breathing or cyanosis, prolonged weakness or inability to stand, and any symptoms suggesting poor perfusion including cold extremities or profound lethargy. Sustained SVT lasting more than brief minutes warrants urgent evaluation, as prolonged rapid rates can precipitate congestive heart failure or cardiovascular collapse. Cats displaying these serious symptoms require emergency veterinary care without delay, as rapid intervention can be life-saving.

Initial examination for suspected SVT involves thorough cardiovascular assessment and evaluation for symptoms consistent with tachyarrhythmia. The veterinarian will carefully auscultate the heart, noting heart rate, rhythm regularity, and any additional abnormalities such as murmurs or gallop rhythms. During active SVT episodes, heart rates are dramatically elevated but typically regular. Pulse quality assessment may reveal rapid, weak pulses. Between episodes, examination may be entirely normal, presenting a diagnostic challenge. Detailed history regarding episode frequency, duration, triggering factors, and associated symptoms helps guide diagnostic testing. Information about any witnessed collapse events, breathing difficulties, or other concerning symptoms is particularly important.

Electrocardiographic evaluation is essential for diagnosing SVT and distinguishing it from other tachyarrhythmias. Standard in-hospital ECG may capture arrhythmia if the cat is experiencing symptoms during examination. However, the paroxysmal nature of many SVT cases means that extended monitoring is often necessary. Holter monitoring over 24 to 48 hours provides continuous rhythm recording that captures intermittent events and quantifies arrhythmia burden. ECG analysis during SVT reveals rapid, regular rhythm with narrow QRS complexes indicating supraventricular origin. P waves may be visible, hidden within QRS complexes, or appearing after QRS complexes depending on the specific SVT mechanism. Distinguishing SVT from sinus tachycardia requires careful attention to rate appropriateness, P wave morphology, and response to vagal maneuvers.

Additional diagnostic testing evaluates for underlying conditions and assesses overall cardiac structure and function. Echocardiography provides detailed assessment of cardiac chambers, walls, valves, and function, identifying structural heart disease that frequently underlies or accompanies SVT. Blood tests including complete blood count, serum chemistry panel, and thyroid hormone levels identify systemic conditions contributing to arrhythmia. Hyperthyroidism screening is particularly important in middle-aged to older cats with new-onset tachyarrhythmia. Blood pressure measurement assesses cardiovascular status. Thoracic radiographs evaluate heart size and detect signs of congestive heart failure including pulmonary edema or pleural effusion.

Differential diagnosis involves distinguishing SVT from other causes of rapid heart rate and determining the specific type of supraventricular arrhythmia present. Sinus tachycardia, a physiologically appropriate rapid rate in response to stress, fever, pain, or other triggers, must be differentiated from pathological SVT. Ventricular tachycardia, originating below the atrioventricular junction, requires ECG differentiation from SVT and has different treatment implications. Atrial fibrillation produces irregular rather than regular rapid rhythms. Atrial flutter has characteristic ECG findings. The specific mechanism of SVT, whether atrioventricular nodal reentry, accessory pathway mediated, or atrial tachycardia, may influence treatment selection though often cannot be definitively determined without specialized electrophysiology studies rarely performed in cats.

Emergency treatment for cats presenting with hemodynamically significant SVT focuses on urgent rhythm control and stabilization. Vagal maneuvers, which increase parasympathetic tone to the heart, may terminate some SVT episodes and can be attempted as initial intervention. Techniques include gentle ocular pressure or carotid sinus massage, though these are often less effective in cats than in dogs or humans. For sustained SVT causing significant symptoms, intravenous medication provides rapid rate control or rhythm conversion. Diltiazem, a calcium channel blocker, effectively slows atrioventricular nodal conduction and may terminate reentrant SVT. Beta-blockers such as esmolol provide another option for acute rate control. For unstable patients with severe hemodynamic compromise, electrical cardioversion under sedation may be necessary.

Medical management of chronic SVT in cats involves daily oral medications selected based on arrhythmia mechanism, underlying disease, and individual patient factors. Calcium channel blockers, particularly diltiazem, are commonly prescribed for long-term SVT management due to their effectiveness in slowing atrioventricular conduction and reducing ventricular rate during SVT episodes. Beta-blockers including atenolol provide rate control and have additional benefits in cats with underlying hypertrophic cardiomyopathy. Sotalol combines beta-blocking properties with class III antiarrhythmic effects and may be effective for some SVT types. Digoxin has been used historically though is less commonly prescribed now due to narrow therapeutic margins and availability of alternatives. Medication selection requires careful consideration of individual patient factors and should be guided by veterinary cardiology expertise.

Surgical and interventional treatment options for SVT are limited in cats compared to human medicine. Radiofrequency catheter ablation, which can cure certain SVT types in humans by destroying the abnormal electrical pathway, is rarely performed in cats due to their small size, limited availability of specialized equipment, and procedural risks. However, ablation may be considered in select cases with refractory arrhythmia and identifiable targets at specialized centers. Surgical intervention may be indicated for underlying conditions contributing to SVT, such as thyroidectomy for hyperthyroid cats or surgical correction of congenital heart defects when feasible.

Supportive care for cats with SVT addresses concurrent conditions and optimizes overall health. Treatment of hyperthyroidism through medication, surgery, or radioactive iodine therapy eliminates an important SVT trigger in affected cats. Management of congestive heart failure, if present, requires diuretics and additional cardiac medications. Maintaining adequate hydration and appropriate electrolyte balance supports normal cardiac electrical function. Stress reduction through environmental modifications may help minimize triggers for arrhythmia in some cats. Pain management and treatment of concurrent illnesses reduces sympathetic activation that can provoke or worsen SVT.

Alternative and complementary approaches may supplement conventional treatment though evidence for specific benefits in feline SVT is limited. Omega-3 fatty acid supplementation supports general cardiac health. Maintaining calm, predictable environments may help minimize stress-related arrhythmia triggers. Adequate rest and avoiding overexertion helps manage symptoms. Taurine supplementation ensures adequacy of this essential nutrient for cardiac function. Any complementary therapies should be discussed with the veterinary team to ensure compatibility with prescribed medications and overall treatment plan.

Treatment decisions for SVT consider arrhythmia severity, episode frequency and duration, underlying disease, patient factors, and owner circumstances. Cats with infrequent, brief, self-terminating episodes may require only monitoring or intermittent treatment. Those with frequent or prolonged episodes causing significant symptoms need daily preventive medication. Treatment costs include diagnostic testing, ongoing medications, and regular monitoring. Expected outcomes vary based on underlying disease and treatment response. Open discussion with the veterinary team about treatment options, goals, and realistic expectations helps owners make informed decisions appropriate for their individual situations.

Recovery timeline for cats with SVT varies considerably based on underlying cause and treatment response. Cats with SVT secondary to hyperthyroidism often show significant improvement within weeks once thyroid hormone levels are controlled. Those started on antiarrhythmic medications typically demonstrate treatment effect within one to two weeks, though optimal dosing may require adjustment over several weeks. Cats that have developed tachycardia-induced cardiomyopathy may show gradual improvement in cardiac function over months once rate control is achieved. For cats without reversible underlying causes, management focuses on long-term control rather than cure, with the goal of minimizing symptomatic episodes and maintaining quality of life.

Post-treatment care for cats with SVT requires dedication to medication protocols and ongoing monitoring. Owners must administer prescribed antiarrhythmic medications consistently, typically once or twice daily depending on the drug used. Monitoring for medication side effects, including lethargy, gastrointestinal upset, or worsening symptoms, allows timely dose adjustment. Activity recommendations depend on individual circumstances, with most well-controlled cats allowed normal activity while avoiding excessive stress or exertion. Follow-up appointments for ECG assessment, echocardiography when indicated, and general evaluation are scheduled based on individual needs, typically every three to six months for stable patients.

Prognosis for cats with SVT depends on underlying etiology, arrhythmia controllability, and overall cardiac health. Cats with SVT secondary to correctable conditions such as hyperthyroidism often have excellent long-term prognoses once the underlying condition is treated. Those with idiopathic SVT or SVT associated with mild structural heart disease generally have good prognoses with appropriate medical management. Cats with significant underlying cardiomyopathy face more guarded prognoses influenced by the type and severity of heart disease. Response to antiarrhythmic medication significantly affects prognosis, with well-controlled cats faring better than those with refractory arrhythmia.

Long-term outlook for cats living with SVT ranges from excellent to guarded depending on individual circumstances. Many cats achieve good arrhythmia control on medication and maintain excellent quality of life for years. Those with underlying cardiomyopathy require concurrent heart disease management and face risks associated with progressive cardiac dysfunction. Regular monitoring allows early detection of treatment failure or disease progression and enables timely intervention. Owners should understand that cardiac disease management is ongoing, with goals focused on symptom control and quality of life rather than cure. Working closely with the veterinary team ensures optimal outcomes for cats with SVT.

Primary prevention of supraventricular tachycardia focuses on identifying and managing conditions that predispose cats to arrhythmia development. Regular veterinary examinations allow detection of heart disease, hyperthyroidism, and other conditions associated with SVT before arrhythmias develop. For breeds known to be predisposed to cardiomyopathy, cardiac screening echocardiography can identify structural heart disease early, allowing proactive management that may reduce arrhythmia risk. Prompt treatment of hyperthyroidism prevents prolonged cardiac stress and associated arrhythmia development. Breeding programs that screen for cardiomyopathy help reduce the prevalence of inherited heart disease in susceptible breeds.

Environmental prevention strategies support overall cardiac health and minimize arrhythmia triggers. Maintaining cats at healthy body weights reduces cardiac workload. Providing low-stress environments with appropriate enrichment, hiding spaces, and predictable routines helps minimize sympathetic nervous system activation that can trigger arrhythmias. Indoor housing protects cats from toxins, trauma, and infectious diseases that could affect cardiac health. Avoiding exposure to known triggers for arrhythmia, including excessive heat, extreme stress, and certain medications or supplements, may help prevent episodes in susceptible cats. Temperature regulation prevents cardiovascular stress from environmental extremes.

Dietary prevention involves providing appropriate nutrition to support cardiac health throughout life. High-quality commercial cat foods formulated to meet feline nutritional requirements provide essential nutrients including taurine, critical for cardiac function. Avoiding excessive sodium intake may benefit cats with cardiac disease. Maintaining adequate hydration supports normal cardiovascular function and electrolyte balance. Cats with diagnosed cardiac disease may benefit from therapeutic cardiac diets formulated to support heart function. Consultation with a veterinarian regarding diet selection is particularly important for cats with known heart disease or risk factors.

Health maintenance practices contribute to cardiac health and arrhythmia prevention. Annual or biannual veterinary examinations allow monitoring of cardiac status through physical examination and additional testing when indicated. Thyroid screening in middle-aged to older cats enables early detection and treatment of hyperthyroidism before cardiac complications develop. Keeping vaccinations current prevents infectious diseases that can affect the heart. Regular parasite prevention protects against heartworm disease. Managing chronic conditions such as kidney disease and diabetes appropriately maintains overall health and reduces cardiac stress.

Early intervention when risk factors or early signs of cardiac disease are identified provides the best opportunity to prevent or minimize arrhythmia development. Cats showing subtle signs of cardiac disease warrant echocardiographic evaluation to assess cardiac structure and function. Early treatment of hyperthyroidism prevents prolonged cardiac effects. Monitoring bloodwork in senior cats helps identify electrolyte disturbances or metabolic conditions before they cause cardiac complications. Working proactively with a veterinarian to monitor cardiac health in predisposed breeds or individual cats with risk factors allows intervention at the earliest possible stage.

Daily management of cats with supraventricular tachycardia requires consistency in medication administration and attention to symptom monitoring. Antiarrhythmic medications should be given at prescribed times each day to maintain stable blood levels and consistent arrhythmia control. Establishing a medication routine that integrates with daily activities reduces the chance of missed doses. Owners should monitor for episodes of rapid heart rate, weakness, or other symptoms that might indicate breakthrough arrhythmia. Keeping a log of any symptomatic episodes, including timing, duration, and associated signs, provides valuable information for veterinary appointments and treatment optimization. Activity levels for most well-controlled cats can remain relatively normal, though avoiding excessive excitement or stress may help minimize episode triggers.

Home environment modifications support the comfort and safety of cats with cardiac arrhythmias. Providing easily accessible resting spots at various heights with low-effort access accommodates cats who may experience intermittent symptoms. Ensuring food, water, and litter boxes are conveniently located minimizes physical exertion during routine activities. Maintaining comfortable ambient temperatures prevents cardiovascular stress from heat or cold extremes. Creating quiet, calm spaces allows cats to rest undisturbed during recovery from symptomatic episodes. Removing or securing potential hazards reduces injury risk for cats who might experience weakness or instability during arrhythmia episodes.

Quality of life maintenance remains the primary goal for cats living with SVT. Most cats with well-controlled arrhythmia can continue enjoying normal feline activities including play, social interaction, and environmental exploration within their individual capabilities. Mental stimulation through puzzle feeders, window perches, and interactive toys keeps cats engaged without requiring excessive physical exertion. Maintaining familiar routines and social bonds provides emotional comfort. Owners should observe their cat's preferences and adjust activities accordingly, recognizing that individual cats have varying energy levels and tolerance for activity. Quality of life assessment focuses on the cat's ability to enjoy daily activities, maintain comfort, and engage with their environment and family.

Ongoing monitoring and regular veterinary care are essential components of long-term SVT management. Owners should learn to assess their cat's heart rate and rhythm when practical, noting any significant changes. Monitoring respiratory rate at rest helps detect early signs of heart failure. Recording any symptom episodes provides important data for treatment evaluation. Regular recheck appointments allow ECG monitoring to assess arrhythmia control and detect any changes requiring treatment adjustment. Echocardiographic reassessment at appropriate intervals tracks underlying cardiac disease. Bloodwork monitoring ensures medication safety and detects concurrent conditions affecting cardiac health.

Caregiver support resources help owners manage the challenges of caring for cats with chronic cardiac conditions. Understanding the nature of SVT, expected disease course, and treatment goals helps owners cope with the emotional aspects of managing chronic illness. Online support communities connect owners of cats with heart disease for shared experiences and practical advice. Open communication with the veterinary team addresses questions and concerns promptly. Financial planning for ongoing medication and monitoring costs ensures sustained treatment capability. Discussing end-of-life considerations with the veterinary team in advance, while difficult, helps owners feel prepared when quality of life decisions become necessary.

Several cat breeds face elevated risk for supraventricular tachycardia primarily due to their predisposition to underlying cardiac diseases, particularly hypertrophic cardiomyopathy, which creates substrate for arrhythmia development. Maine Coons are among the most well-documented breeds for inherited hypertrophic cardiomyopathy, with identified genetic mutations affecting cardiac muscle proteins. This structural heart disease predisposes to atrial enlargement and electrical abnormalities that can trigger SVT. Ragdolls similarly carry genetic mutations associated with cardiomyopathy and face elevated cardiac disease and arrhythmia risk. British Shorthairs have documented HCM predisposition that may translate to increased SVT risk. Persian cats and related breeds including Himalayans and Exotic Shorthairs also show increased cardiomyopathy prevalence.

Other breeds with recognized cardiac disease predisposition include Sphynx cats, which have documented hypertrophic cardiomyopathy risk, and Bengal cats with reported cardiomyopathy prevalence in some populations. Norwegian Forest Cats, Siberian cats, and Scottish Folds have been reported with increased cardiomyopathy in certain bloodlines. Devon Rex and Cornish Rex cats may carry elevated risk in some families. American and British Shorthair cats have documented cardiomyopathy predisposition. Mixed breed cats can certainly develop SVT, with individual risk influenced by unknown genetic factors potentially inherited from purebred ancestors.

Screening recommendations for breeds at risk include echocardiographic examination at appropriate intervals to detect structural heart disease before arrhythmias develop. Genetic testing for specific HCM mutations is available for Maine Coons and Ragdolls through the Veterinary Cardiac Genetics Laboratory. Breed clubs and responsible breeders often require cardiac screening as part of breeding programs. Prospective owners of high-risk breeds should request documentation of parental cardiac screening and consider screening their own cats. Annual veterinary examinations with careful cardiac auscultation help detect early signs of heart disease, with echocardiography recommended when abnormalities are found or for routine screening in predisposed breeds.

Supraventricular tachycardia commonly co-occurs with structural cardiac diseases that provide the substrate for arrhythmia development. Hypertrophic cardiomyopathy, the most common heart disease in cats, frequently underlies SVT due to the atrial enlargement and myocardial changes that predispose to abnormal electrical activity. Dilated cardiomyopathy, restrictive cardiomyopathy, and other structural cardiac abnormalities similarly predispose to supraventricular arrhythmias. Hyperthyroidism is a frequent concurrent condition, particularly in older cats, and directly promotes tachyarrhythmia through its cardiac effects. Congestive heart failure may develop in cats with progressive cardiac disease, adding fluid management to the treatment requirements for cats already dealing with arrhythmias.

Conditions with similar presentations require differentiation from SVT during diagnostic evaluation. Sinus tachycardia, a physiologically appropriate rapid heart rate response to stress, fever, pain, or other triggers, must be distinguished from pathological SVT. Ventricular tachycardia, originating below the AV junction, produces rapid rates but has different ECG characteristics and treatment implications. Atrial fibrillation causes rapid, irregular heart rates unlike the regular rhythm of most SVT types. Atrial flutter has characteristic ECG findings distinguishing it from other supraventricular arrhythmias. Accurate ECG diagnosis ensures appropriate treatment selection.

Complications arising from SVT include progression of underlying heart disease, development of heart failure, and tachycardia-induced cardiomyopathy from sustained rapid rates. Prolonged, uncontrolled SVT can cause progressive ventricular dysfunction that may or may not be reversible with rate control. Cats with underlying cardiomyopathy remain at risk for arterial thromboembolism regardless of arrhythmia management. Medication side effects may occur with antiarrhythmic therapy, requiring monitoring and potential treatment adjustment. Secondary organ dysfunction from reduced cardiac output can develop in cats with severe, uncontrolled tachyarrhythmia. Recognition of these potential complications guides monitoring and treatment adjustments throughout disease management.